Stock CASI CASI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-24 pm EDT 		5-day change 1st Jan Change
3.546 USD +9.44% Intraday chart for CASI Pharmaceuticals, Inc. +7.45% -50.47%
May. 15 Sector Update: Health Care Stocks Advance in Afternoon Trading MT
May. 15 CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study MT

Evolution of the average Target Price on CASI Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a109be7fed57c1161b80c5f7698d.ewdKP-5j6IVd38PVUJwBrqoyXTlBwzXyXCoSplsP86I.HT8ve6wKn_U2k7CKJ6hO58xgBHcYl3enGBJI8BR4uuBPYSdtmSKFsBjsjg~4a48c1b98e44d11368f77b9c39e962aa

Analyst Recommendations on CASI Pharmaceuticals, Inc.

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating MT
BTIG Raises CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Adjusts CASI Pharmaceuticals' Price Target to $3 from $4, Keeps Buy Rating MT
CASI PHARMACEUTICALS : BTIG Initiates CASI Pharmaceuticals at Buy Rating With $4 Price Target MT
CASI PHARMACEUTICALS : HC Wainwright Adjusts CASI Pharmaceuticals PT to $4 From $3.50, Maintains Buy Rating MT
CASI PHARMACEUTICALS : Mizuho Security Initiates Coverage on CASI Pharmaceuticals With Buy Rating, $3.80 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.546 USD
Average target price
6 USD
Spread / Average Target
+69.20%
High Price Target
6 USD
Spread / Highest target
+69.20%
Low Price Target
6 USD
Spread / Lowest Target
+69.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CASI Pharmaceuticals, Inc.

HC Wainwright
BTIG
Oppenheimer
Mizuho Securities

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CASI Stock
  4. Consensus CASI Pharmaceuticals, Inc.